Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only Biopharma’s Sickly September Stephen Taub Ken Poliziani, Chief Marketing Officer, PGIM Institutional Investor A Different Ask of Global Equities as Investors Seek Downside Protection Sponsored by Schroders